COMMUNIQUÉS West-GlobeNewswire

MedX Holdings Accelerates Growth: Expanding Lazydaze Franchise Footprint, Unveiling Major Product Innovations, and Strengthening Brand Infrastructure
17/06/2026
Lazydaze Coffeeshop - Here We Grow Again Austin Texas, June 17, 2026 (GLOBE NEWSWIRE) -- FOR IMMEDIATE RELEASE MedX Holdings Accelerates Growth Strategy: Expanding Lazydaze Franchise Footprint, Unveiling Major Product [...]
Ocular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with Submission Planned for Fourth Quarter 2026
17/06/2026
Per May 2026 Type C meeting, AXPAXLI NDA for wet AMD to be based on SOL-1 Week 52 efficacy and safety plus interim SOL-R safety data Ocular to conduct interim SOL-R safety analysis in 4Q 2026 to reach >300 patients [...]
NeOnc's Global Expansion Accelerates After Abu Dhabi IND Approval for NEO212
17/06/2026
InvestorsTape.com Closely Watching NTHI Ahead of Multiple Clinical, Regulatory, and Data Catalysts DALLAS, June 17, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings (NASDAQ: NTHI) is rapidly emerging as a [...]
Cosmos Health Signs 2.86 Million-Unit Contract Manufacturing Agreement With Pharmex S.A. Across Three Dermatological Products
17/06/2026
CHICAGO, June 17, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that, through its wholly [...]
Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform
17/06/2026
Raanana, Israel, June 17, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, [...]
Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study
17/06/2026
Lead Cell Therapy Demonstrated Complete Tumor Clearance and 100% Long-Term Survival in Preclinical Ovarian Cancer Models; Multiple Regulatory, Manufacturing and Clinical Catalysts Expected Through 2027 CAMBRIDGE, Mass [...]
Zelluna ASA: Contemplated Private Placement and Retail Offering to Strengthen its Position Ahead of Initial Clinical Data
17/06/2026
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, SOUTH AFRICA OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE [...]
Precision Neuroscience™ Wins 2026 Webby Award; Earns Back-to-Back Fast Company World Changing Ideas Honor
17/06/2026
Both recognitions cite the Layer 7 cortical interface and its potential to restore independence for people living with paralysis NEW YORK, June 17, 2026 (GLOBE NEWSWIRE) -- Precision Neuroscience Corporation (Precision [...]
Glass House Brands Announces its Deconsolidation of its Dual-Use Business and its Application for Uplisting of Shares to NYSE
17/06/2026
LONG BEACH, Calif. and TORONTO, June 17, 2026 (GLOBE NEWSWIRE) -- Glass House Brands Inc. ("Glass House" or the “Company”) (CBOE CA: GLAS.A.U) (OTCQX: GLASF) today announced that it has applied to list its subordinate [...]
Christian Wichert appointed Chief Executive Officer to lead next phase of growth
17/06/2026
Senior executive across industrial biotechnology and consumer markets with strong expertise in commercialization joins AMSilk as the Company advances from development through scale-up to market growth The announcement [...]
NexTel Medical Outlines its Revenue Model Using the Innovation of Tomorrow: Synergy of Advanced Medical Technologies and Massive Sales Infrastructure Primed to Drive Exponential Growth
17/06/2026
BOCA RATON, Fla., June 17, 2026 (GLOBE NEWSWIRE) -- NexTel Medical Corp. (f/k/a Exousia Pro, Inc.) (OTCID: MAJI) today announced a strategic pivot, evolutionary restructuring, and operational alignment designed to [...]
HMNC Brain Health appoints Dr. Bjørn Grønning as Chief Medical Officer
17/06/2026
Pharmaceutical executive and physician with strong experience in global research and development Over 20 years’ experience in all stages of clinical development across multiple indications, including neurology and [...]
Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy
17/06/2026
TORONTO and BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. (“Sernova” or the “Company”) (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO), a leading regenerative medicine company focused on developing [...]
Trading in GN Store Nord shares by board members, executives and associated persons
17/06/2026
GN Store Nord has received notification pursuant to article 19 of regulation (EU) no. 596/2014 of the below transactions related to shares in GN Store Nord made by persons discharging managerial responsibilities in GN [...]
Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society
17/06/2026
Presentations included analyses of natural history and adverse outcomes in congenital hyperinsulinism (HI), as well as previously reported results from the Company’s Phase 3 sunRIZE study in congenital HI and a case [...]
Trevi Therapeutics Announces Upcoming June and July Event Schedule
17/06/2026
NEW HAVEN, Conn., June 17, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the [...]
Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.
17/06/2026
- Up to $125 million in additional borrowing capacity provides further strategic flexibility - - $50 million of additional capacity funded at amendment closing - WALTHAM, Mass., June 17, 2026 (GLOBE NEWSWIRE) -- Dyne [...]
uniQure Announces Plan for BLA Submission for AMT-130 in Huntington’s Disease
17/06/2026
~ 3-year analysis from the Phase I/II study can serve as the primary basis of a Biologics License Application for accelerated approval with FDA ~ ~ Company intends to submit the BLA in third quarter of 2026 ~ LEXINGTON [...]
Step Pharma advances dencatistat into phase 2 clinical trial for essential thrombocythaemia
17/06/2026
Saint-Genis-Pouilly, France, 17 June 2026 – Step Pharma (“the Company”), the global leader in CTPS1 inhibition for targeted cancer treatment, today announces that it has advanced dencatistat, the Company’s first-in- [...]

Pages